The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

HIV Infections Clinical Trial

Official title:

A Randomized, Double-Blind, Parallel-Group, Multicenter Trial to Evaluate the Safety and Efficacy of 1592U89 in Combination With Lamivudine (3TC) and Zidovudine (ZDV) Versus 3TC/ZDV in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects With CD4+ Counts >= 100 Cells/mm3

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00002389
• Other study ID #: 238D
• Status: Completed
• Phase: Phase 3
• First received: November 2, 1999
• Last updated: June 23, 2005

Study information

• Verified date: November 1998
• Source: NIH AIDS Clinical Trials Information Service
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To compare the durability of the viral load response following 48 weeks of treatment with 1592U89/lamivudine (3TC)/zidovudine (ZDV) versus 3TC/ZDV alone. To compare the early antiviral activity following 16 weeks treatment with 1592U89/3TC/ZDV versus 3TC/ZDV alone as demonstrated by the proportion of subjects with viral load < 400 copies/ml, plasma HIV-1 RNA profiles and CD4+ profiles. To assess the safety and tolerance following 16 and 48 weeks of treatment with 1592U89/3TC/ZDV versus 3TC/ZDV alone.

Description:

This study compares the safety and efficacy of 1592U89 in combination with 3TC and ZDV versus control therapy with 3TC and ZDV alone. If a patient has two consecutive HIV-1 RNA measurements of >= 400 copies/ml (performed at least one week apart) he or she has the option to switch to open-label therapy with 1592U89/3TC/ZDV, to receive the remaining randomized treatment, or to discontinue study medication. If this criterion is not met, patients continue their randomly assigned therapy until the last patient has completed 48 weeks of therapy. Once patients enter the open-label phase, investigators may add or substitute non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, or protease inhibitors for 3TC and/or ZDV according to their standard practice once patients enter the open-label phase.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 210
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 13 Years and older

Eligibility

Inclusion Criteria

Concurrent Medication:

Allowed:

• Local treatment for Kaposi's sarcoma.

• Hematologic supportive therapy with GM-CSF, G-CSF, or erythropoietin.

Patients must have:

• HIV-1 infection as documented by a licensed HIV-1 antibody ELISA and confirmed by either Western blot detection of HIV-1 antibody or positive HIV-1 blood culture.

• One screening CD4 lymphocyte cell count >= 100 cells/mm3 within 14 days prior to study drug administration.

• No active or ongoing AIDS-defining opportunistic infection or disease.

• Signed, informed consent from parent or legal guardian for patients under 18 years of age.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions and symptoms are excluded:

• Malabsorption syndrome or other gastrointestinal dysfunction that might interfere with drug absorption or render the patient unable to take oral medication.

• Serious medical conditions such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction, that, in the opinion of the investigator, would compromise the safety of the patient.

Concurrent Medication:

Excluded:

• Foscarnet therapy.

• Immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide, anti-cytokine agents, or interferons.

• Cytotoxic chemotherapeutic agents and antioxidants.

Concurrent Treatment:

Excluded:

Radiation therapy.

Patients with the following prior conditions are excluded:

History of clinically relevant pancreatitis or hepatitis within the last 6 months.

Prior Medication:

Excluded:

• Prior antiretroviral therapy.

• Vaccination within the past 3 months given as part of an investigational HIV vaccine trial.

• Chemotherapeutic agents within 30 days of study drug administration.

• Immunomodulating agents such as systemic corticosteroids, interleukins or interferons, within 30 days of study drug administration.

Prior Treatment:

Excluded:

Radiation therapy within 30 days of study period. Current alcohol or illicit drug use that, in the opinion of the investigator, may interfere with the patient's ability to comply with the dosing schedule and protocol evaluations.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Abacavir sulfate

• Lamivudine

• Zidovudine

Locations

Country	Name	City	State
Canada	Toronto Gen Hosp	Toronto	Ontario
Puerto Rico	San Juan AIDS Program	Santurce
United States	East Bay AIDS Ctr	Berkeley	California
United States	Boston Med Ctr / Evans - 556	Boston	Massachusetts
United States	Rush Med College / Rush Presbyterian - St Luke's Med Cen	Chicago	Illinois
United States	Univ of Cincinnati / Holmes Hosp	Cincinnati	Ohio
United States	Dr Nicholaos Bellos	Dallas	Texas
United States	Duke Univ Med Ctr / Dept of Medicine	Durham	North Carolina
United States	Baylor College of Medicine / Dept of Medicine	Houston	Texas
United States	Kraus Med Partners	Los Angeles	California
United States	Univ of Miami Dept of Medicine	Miami	Florida
United States	Harlem Hosp	New York	New York
United States	St Vincent's Hosp and Med Ctr / AIDS Ctr	New York	New York
United States	Saint Michael's Med Ctr / Dept of Infectious Diseases	Newark	New Jersey
United States	Georgetown Univ Med Ctr	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Glaxo Wellcome

Countries where clinical trial is conducted

United States,  Canada,  Puerto Rico,